Véronique Millot

[Irena Vukusic @irena_vukusic]

#ECTRIMS2022 #SFSEP @VukusicS @XtineLebrunF Romain Marignier

[Véronique Millot @VMillot5]

#OFSEP #ECTRIMS2022

[ECTRIMS @ECTRIMS]

Nous sommes très heureux de voir que vous appréciez #ECTRIMS2022, merci de nous en faire part !

[Véronique Millot @VMillot5]

#ECTRIMS2022
#OFSEP

Visit the OFSEP, French MS registry
BOOTH B25

[Birgit Bauer @Birgitpower]

Poster Session at #ECTRIMS2022 and I Wonder why study / research projects don’t differ in women and men when it comes to find out thing. There are differences and we should have data about it. Or find. #ms #datasaveslives

[MS Centrum Amsterdam @MScentrum020]

Uitdehaag: 'MS can run trough your fingers like loose sand. But sand is more. When grains are connected in a clever way it can be strong, you can built upon it.' Introduction of sand artist #GertvanderVijver at the opening op #ECTRIMS2022

[MS Centrum Amsterdam @MScentrum020]

Welcome to #ECTRIMS2022! Let's share our knowledge on #MS and together make a world free of MS.

[Véronique Millot @VMillot5]

@SNCFTERAURA Merci. Ce TER a fini par arriver mais là nous sommes bloqués en pleine voie sans info. En avez-vous à nous communiquer ?
Merci par avance.

[SNCF TER Auvergne-Rhône-Alpes @SNCFTERAURA]

🗓 Pour fêter les 2 ans de ce fil Twitter, TER Auvergne-Rhône-Alpes vous offre 1 abonnement illico Annuel ! Pour participer :
➡Abonnez-vous au compte @SNCFTERAURA
➡Likez et retweetez ce post
Le gagnant sera tiré au sort le 19 septembre.
Plus d'infos: https://t.co/S11XoKyTMx

[Véronique Millot @VMillot5]

#ECTRIMS2019
#OFSEP

POSTER session 3
Linked with OFSEP
P1139
P1323
P1381
P1388
P1418

[Irena Vukusic @irena_vukusic]

Poster session 12:15
P1388 - Long-term effectiveness, safety and tolerability with fingolimod treatment in patients with multiple sclerosis in real-world treatment settings in France: final results of the VIRGILE study, Caroline Papeix, Paris, FR
#ECTRIMS2019

[Irena Vukusic @irena_vukusic]

Poster session 12:15
P1323 - Compared CSF biomarker profile of AQP4-Ab, MOG-Ab and double seronegative NMOSD reveals specificities with potential therapeutic implications, Eric Thouvenot, Nîmes, FR
#ECTRIMS2019

[Irena Vukusic @irena_vukusic]

Poster session 12:15
P1418 - Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis, Sifat Sharmin, AU
#ECTRIMS2019

[Irena Vukusic @irena_vukusic]

#ECTRIMS2019 #OFSEP

[Véronique Millot @VMillot5]

#ECTRIMS2019
#OFSEP
Booth D32
Meet with the OFSEP coordination centre

[Irena Vukusic @irena_vukusic]

09:34 Hall A "Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on OFSEP data" by Emmanuelle Leray #ECTRIMS2019

[christine lebrun frenay @XtineLebrunF]

#ECTRIMS2019 Prof Sandra VUKUSIC had a powerful talk about vaccines and DMT #VaccinesWork # https://t.co/iq4kCetezO

[Véronique Millot @VMillot5]

#ECTRIMS2019
Fabien Rollot
Poster session 2

[Véronique Millot @VMillot5]

#ECTRIMS2019
#OFSEP

17:15 - 19:15 Poster session 2
Effectiveness of subcutaneous interferon beta-1a 22/44 μg versus teriflunomide
in newly treated patients with multiple sclerosis. A study in a French nationwide cohort
of multiple sclerosis: OFSEP
F. Rollot (Lyon, FR)

[Véronique Millot @VMillot5]

#ECTRIMS2019
#OFSEP

at 16:15 HALL B
Free communication 5: MOG
242 - MOG antibodies and MS in adults: a large multicentre cross-sectional study.
Alvaro Cobo-Calvo.